Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer MarketBeat
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Yahoo Finance
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data TipRanks
Sanju Pal's endometriosis case: How painful periods impact workplace performances, IVF specialist weighs... Moneycontrol.com
Endometriosis diagnosis is often limited by the resolution of conventional imaging techniques (ultrasound/non-targeted MRI) as well as the invasiveness and recurrence risks associated with laparoscopy. To overcome these challenges, we …
Endometriosis is a disease characterized by fibrosis and adhesions. There are still no treatment methods targeting these conditions. One reason for this is the lack of useful animal models to …
We investigated whether ovarian endometriomas uniformly express functional FSH receptors (FSHR) and respond to FSH by activating transcriptional programs that drive aromatase and steroid hormone production. Endometrioma cyst capsules were …
Dysmenorrhea is a debilitating symptom in patients with endometriosis, contributing significantly to disease burden. While the relationship between body mass index (BMI) and dysmenorrhea in these patients is unclear, emerging …
Endometriosis (EM) is driven by immune dysregulation and macrophage dysfunction, yet the underlying mechanisms remain unclear. Here, metabolomic profiling revealed excessive itaconate accumulation in EM lesions, primarily due to elevated …
Ureteral endometriosis (UE) is a rare but potentially devastating manifestation of deep infiltrating endometriosis, often remaining asymptomatic until irreversible renal damage occurs. We present the case of a 42-year-old woman …